therapies for aggressive cancer and leukemia. An NF-kappa B
inhibitor named dehydroxymethylepoxyquinomicin
Yagudin, T.,
Zhao, Y.,
Gao, H.,
Zhang, Y.,
Yang, Y.,
Zhang, X.,
Ma, W.,
Daba, T.M.,
Ishmetov, V.,
Kang, K.,
Yang, B.,
Pan, Z. (2020)
infarction in order to facilitate the development of
novel therapy.
Inhibitor of apoptosis
CAI, B.,
MA, W.,
WANG, X.,
SUKHAREVA, N.,
HUA, B.,
ZHANG, L.,
LI, X.,
LI, S.,
LIU, S.,
YU, M.,
XU, Y.,
SONG, R.,
XU, B.,
YANG, F.,
HAN, Z.,
DING, F.,
HUANG, Q.,
YU, Y.,
ZHAO, Y.,
WANG, J.,
BAMBA, D.,
PAN, Z.,
YANG, B.,
XU, J.,
ZAGIDULLIN, N.,
LI, F.,
TIAN, Y. (2020) ) phosphorylation and reduced its nuclear translocation by binding PP1A. Verteporfin, a YAP1
inhibitor decreased Lnc
CIRCULATING MICRORNA AS
NOVEL POTENTIAL BIOMARKERS FOR THE DIAGNOSIS OF HIGHLY MALIGNANT GLIOMAS
KURKINA, M.V.,
MIHAYLOVA, S.V.,
BAIDAKOVA, G.V.,
SAIFULLINA, E.V.,
KOROSTELEV, S.A.,
PYANKOV, D.V.,
KANIVETS, I.V.,
YUNIN, M.A.,
PECHATNIKOVA, N.L.,
ZAKHAROVA, E.YU (2020) identified a total of 21 variants, 9 of which were
novel: c.127 + 1G > T, с.471_473delCGA, c.161 T > C (p